Norwegian biotech firm Pharmaq achieved 12 percent growth in turnover last year, while operating profit improved by almost 15 percent. Growth in sales of lice treatments contributed substantially.
Sales last year totaled NOK 569.8 million (€67.2 million/$72.8 million), up from NOK 509.3 million (€60.1 million/$65 million) in 2013.
Operating profit improved to NOK 119.3 million (€14.1 million/$15.2 million) from NOK 104 million (€12.3 million/$13.3 million) in the previous year for the company.
According to the board of directors’ annual report; “The main reason for the growth in sales is due to a substantially stronger position in the Norwegian vaccine market and growth in revenue from sales of salmon lice treatments.”
The
